FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesCommercialization of Personalized Medicines
Topic: Pharma Industry
Report
Members
Overview of DtP Models for Clinical Trials
Topic: Conference
Video
Members
4G Clinical webinar - Mitigating Clinical Supply Chain Risk as the Pandemic Continues
Topics: COVID-19, Project Management, Supply Chain
Webinar
Free
